CoChat

The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease

Open access
Yanartas, Ömer, Kani, Haluk Tarik, Bicakci, Ercan, Kilic, Irem, Banzragch, Mutse, Acikel, Cengizhan, Atug, Ozlen, Kuscu, Kemal, Imeryuz, Nese, Akin, Hakan · 2016 · Neuropsychiatric Disease and Treatment

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; none of the 21 sources its claims cite is checked for support yet.

Abstract

OBJECTIVE: Depression and anxiety are common disorders in inflammatory bowel disease (IBD). Our aim is to prospectively determine the effect of psychiatric treatment on scores for depression, anxiety, quality of life (QoL), and sexual dysfunction in an outpatient population diagnosed with IBD and also anxiety and/or depression disorder. PATIENTS AND METHODS: Patients who scored higher than the cutoff point on the Hospital Anxiety Depression Scale were referred for further structured psychiatric evaluation and determination of the need for psychiatric drug treatment. Patients who underwent drug therapy completed Short Form-36 (SF-36) and the Arizona Sexual Experience Scale at baseline and after 6 months of follow-up. RESULTS: Major depressive disorder and generalized anxiety disorder were the most common diagnoses. After 6 months, 47 patients had completely adhered to drug treatment (group A), whereas 20 were nonadherent (group B). In group A, all domains of SF-36, Arizona Sexual Experience Scale, depression/anxiety scores, and Crohn's disease activity index were statistically improved after treatment when compared with the baseline. In group B, the three domains of SF-36, platelet count, and mean corpuscular volume were worse between baseline and at 6 months. CONCLUSION: In IBD patients having any psychiatric disorder, 6 months of antidepressant drug treatment is associated with an improvement in depression, anxiety, QoL, and sexual functioning scores, as well as an improvement in Crohn's disease activity index. On the other hand, insufficient psychiatric treatment seems to be related to a poor QoL.

Overview

CoChat Summary

## TL;DR

This prospective outpatient study found that 6 months of antidepressant psychiatric treatment in IBD patients with psychiatric disorders was associated with improved depression, anxiety, quality of life, sexual function, and Crohn’s disease activity index. Patients who did not adhere to treatment did not show these benefits and had some worsening of QoL-related measures.

## Key findings

  • Of 214 invited IBD outpatients, 177 completed screening; 70 had HADS scores above cutoff, and 67/70 (95.71%) were diagnosed with a psychiatric disorder by SCID-I. The most common diagnosis was major depressive disorder (43.3%).
  • After 6 months, the adherent treatment group (group A, n=47) showed statistically significant improvement in HAD-A, HAD-D, all SF-36 domains, ASEX, hemoglobin, and CDAI compared with baseline.
  • In the nonadherent group (group B, n=20), SF-36 items SF-3 and SF-8 worsened, and platelet count and mean corpuscular volume were worse between baseline and 6 months.
  • Side effects were reported by 19/67 treated patients (33.3%); only 5 of those 19 (26.3%) discontinued medication, and discontinuation was due to new-onset sexual dysfunction (3 cases), weight gain (1), and fatigue/drowsiness (1).

## Methods

  • Prospective outpatient study at a single IBD clinic (Marmara University Hospital) from June 1, 2013 to June 1, 2014; 214 sequential IBD outpatients were invited, 177 were analyzed after exclusions.
  • Screening used HADS, followed by psychiatrist-administered SCID-I for those above cutoff; patients diagnosed with psychiatric disorder were offered antidepressant treatment and followed for 6 months.
  • Outcomes were measured at baseline and 6 months using SF-36, Arizona Sexual Experience Scale (ASEX), disease activity indices (CDAI for Crohn’s disease, modified Mayo score for ulcerative colitis), and laboratory tests; analyses included paired-samples t-tests, between-group tests, correlations, and logistic regression.

## Limitations

  • The paper explicitly states that subtype-specific comparisons of IBD were not possible because group A and group B were relatively small.
  • The follow-up period was relatively short, as stated in the paper.
  • The study population was mostly outpatient patients in remission, so the text notes that findings may not generalize well to more flare-prone patients; this is an evident limitation from the sample described.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/ndt.s106039

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow chart of the study: the effects of psychiatric treatment in inflammatory bowel disease patients. Notes: *HADS anxiety score >7 described as depression and anxiety score >10 described as anxiety. Abbreviations: ASEX, Arizona Sexual Experience Scale; CD, Crohn’s disease; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory bowel disease; SCID, Structured Clinical Interview for DSM-IV Axis I Disorders; SF-36, Short Form-36; UC, ulcerative colitis.
Figure 1 Flow chart of the study: the effects of psychiatric treatment in inflammatory bowel disease patients. Notes: *HADS anxiety score >7 described as depression and anxiety score >10 described as anxiety. Abbreviations: ASEX, Arizona Sexual Experience Scale; CD, Crohn’s disease; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory bowel disease; SCID, Structured Clinical Interview for DSM-IV Axis I Disorders; SF-36, Short Form-36; UC, ulcerative colitis.CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 12 Not checked · 33 Own results and interpretations

20 more claims

Create a free account to see all 45 claims and to verify the 21 references still open.

See all claims — free account
  • It may state two separate claims as one. 15
  • Probably not a substantial claim. 6
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Cited by

See all 69

Metadata

Authors
Yanartas, Ö., Kani, H. T., Bicakci, E., Kilic, I., Banzragch, M., Acikel, C., Atug, O., Kuscu, K., Imeryuz, N., & Akin, H.
Affiliations
Marmara University (TR)
Venue
Neuropsychiatric Disease and Treatment
Published
2016-03
Volume
12
Pages
673
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W2316004356
Cited by
69
References
32
Citations by year
2026: 1 · 2025: 6 · 2024: 9 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 3
FWCI
5.92
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Marmara Üniversitesi
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
inflammatory bowel disease, depression, anxiety, quality of life, sexual dysfunction, antidepressant treatment, medication adherence, CDAI, major depressive disorder, generalized anxiety disorder, psychiatric comorbidity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. https://app.cochat.ai/papers/10.2147/ndt.s106039
The paper
Yanartas, Ö., Kani, H. T., Bicakci, E., Kilic, I., Banzragch, M., Acikel, C., Atug, O., Kuscu, K., Imeryuz, N., & Akin, H. (2016). The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s106039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.